That’s about the value of US sales of Ozempic generated in 2022 — a drug that has resulted in such enormous flows of money to its Danish producers that it’s impacting the country’s monetary policy.
Interesting that you’re referring here, as a counterfactual, to a drug that was put on hold for a very long time because weight loss was not a large enough market—only managed to be developed with diabetes as the focus target, and got repurposed for weight loss later.
Also, GLP-1 agonists were a thing for cca 16 years, but the tweaks and research necessary to make them suitable enough for mass-market weight loss only came about in the last 6, and the approval process and scaleup of production took a long time.
Do you believe this would have been faster had weight loss been a 10x bigger market for whatever reasons?
Well, it’s only the summary of a single section—the post is essentially an introduction to the chapters and then this summary so I think it does a good enough job for 2+ paragraph readers.